AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00371332
Drug: Minocycline HCL Microspheres
RxNorm normalized name: minocycline HCl microspheres
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01383460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
Trial: NCT02070510
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).
Trial: NCT01107145
Drug: Artemether-Lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
Trial: NCT04685993
Drug: LPCN 1144
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral LPCN 1144, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose).
Trial: NCT01015014
Drug: AN3365
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LP, 600 mg vial; reconstituted in Normal Saline
Trial: NCT01015014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride for injection
Trial: NCT02231372
Drug: Berodual® Respimat® solution for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00596219
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib
Trial: NCT00224263
Drug: Lingzhi (Ganoderma)
RxNorm normalized name: Ganoderma lucidum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01769677
Drug: 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
Trial: NCT04474340
Drug: COVID-19 Convalscent Plasma
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The source convalescent plasma is typically collected from individuals who have recovered from COVID-19 which contains antibodies titer against SARS-CoV-2 and is administered to patients with COVID-19. Donor eligibility criteria and qualification are based on American Accredited Blood Banks ( AABB) standards , including questionnaires and relevant transfusion-transmitted infections testing are performed. Furthermore, pathogen inactivation will be performed for each unit, CCP was only collected from individuals who meet all donor eligibility requirements (21 CFR 630.10 and 21 CFR 630.15). Donors must be found positive at a diagnostic test of nasopharyngeal swab at the time of illness and positive serological test for SARS-CoV-2 antibodies after recovery. All donors should have negative HLA antibodies.
Trial: NCT00133406
Drug: glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4gm/kg; ie up to 8.3gm/d, with juice daily for 10 days
Trial: NCT00133406
Drug: zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg twice weekly for 12 months
Trial: NCT02548936
Drug: Ezetimibe+Simvastatin Drug Combination
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
Trial: NCT02900352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00028717
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00028717
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03387605
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo given 2 times daily for 72 hours
Trial: NCT00061789
Drug: SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00421278
Drug: MK0633
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
Trial: NCT00473005
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2 bid, Oral
Trial: NCT02848287
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1\*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
Trial: NCT01579019
Drug: RO5024048
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg po bid, 24 or 26 weeks
Trial: NCT03351478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.
Trial: NCT03351478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.
Trial: NCT03289338
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5mg intravenous once a month for 3 months
Trial: NCT03289338
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline intravenous once a month for 3 months
Trial: NCT05105074
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 - Patients will not receive intrathecal morphine. Patients will receive only bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
Trial: NCT01131182
Drug: Comparator: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription
Trial: NCT00231790
Drug: MK-0634 50 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one capsule orally, once daily in morning
Trial: NCT00231790
Drug: MK-0634 125 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one or three capsules orally, once daily in morning
Trial: NCT00231790
Drug: Placebo for MK-0634
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one, two, three or four capsules orally once daily in morning
Trial: NCT00785356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 capsules daily for 3 months
Trial: NCT01820585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT02544451
Drug: LUM/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age).~LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older).
Trial: NCT00687661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebo pill once weekly for 24 months
Trial: NCT01119339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily
Trial: NCT01119339
Drug: Reference
RxNorm normalized name: Loreal Preference Dark Auburn 4R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference, once daily
Trial: NCT00434824
Drug: Oral testosterone undecanoate (Andriol)
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses
Trial: NCT00434824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment for 12 months with placebo in divided doses
Trial: NCT02150343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose every 4 weeks
Trial: NCT00688558
Drug: JTT-705 600 mg and simvastatin 40 mg
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Simvastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, immediately following breakfast and/or assessments
Trial: NCT00688558
Drug: Placebo and simvastatin 40 mg
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Simvastatin 40 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
Trial: NCT01290718
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900mg/m2 bid po on days 1-14 of each 3-week cycle
Trial: NCT00473655
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg or 20mg
Trial: NCT02685345
Drug: DS-8500a 25 mg
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02685345
Drug: DS-8500a 75 mg
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00915902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (corn oil), two 1-gram capsules taken twice daily for 8 weeks
Trial: NCT01013974
Drug: GSK573719 250 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
Trial: NCT01013974
Drug: GSK573719 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
Trial: NCT01013974
Drug: GSK573719 matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
Trial: NCT00651105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00927030
Drug: supplemental liquid melatonin
RxNorm normalized name: melatonin Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid melatonin will be given to the parent. There are 4 dose levels (1mg, 3mg, 6 mg, and 9mg)of melatonin that will be used at 3 week intervals. The child will start with 1mg and the dose will be increased at 3 week intervals until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. Once this goal is reached the child will stay on that dose through the remainder of the study.
Trial: NCT00927030
Drug: flavored liquid or liquid supplemental melatonin
RxNorm normalized name: melatonin Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single blind for parents at initial 3-weeks dose period of 1 mg melatonin for 18 children where 3/18 children will receive placebo and 15/18 children will receive melatonin study drug. Each bottle will be labeled as: Flavored liquid placebo/or liquid melatonin. After this initial 3-week period all children will receive known melatonin in bottles that state this.
Trial: NCT02478710
Drug: Aerosolized Tobramycin or Vancomycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.
Trial: NCT02987010
Drug: IDH305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocitrate Dehydrogenase 1 inhibitor
Trial: NCT02478710
Drug: Aerosolized Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
Trial: NCT03037073
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
Trial: NCT01958905
Drug: Artemether-lumefantrine fixed combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01499485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily morning ABGA:~* If actual bicarbonate \> 26 mmol/L and pH \> 7.35: administration of enteral capsule of placebo.~* If actual bicarbonate \> 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH \> 7.35 and then administer enteral capsule of placebo.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day.
Trial: NCT04474483
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
Trial: NCT00005998
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01307956
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01307956
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04611321
Drug: IBI318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI318 will be given fixed dose via intravenous (IV) infusion on Day 1 of each 14-day cycle until disease progression or loss of clinical benefit.
Trial: NCT02758782
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00296400
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01014533
Drug: Placebo dispensed to subject.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 11 days, (one pill at bedtime on nights 1 and 2, 2 pills at bedtime on nights 3-10, and 1 pill at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on nights 8 - 10 of medication so their sleep data can be compared.
Trial: NCT03710330
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 110 ml normal saline IV just before skin incision
Trial: NCT01204034
Drug: Inuvair
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
Trial: NCT01663402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
Trial: NCT01774591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
Trial: NCT02679664
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg tablet of rosuvastatin
Trial: NCT02786992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01690663
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01445587
Drug: Part 1; Cohort 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 125mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 125mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the dose will be escalated to 150mg GSK2110183 for the subject enrolled to Cohort 2. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
Trial: NCT03932019
Drug: Jitongning tablet(High-dose )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jitongning tablet,3tablets,bid,treat 12 weeks
Trial: NCT03932019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jitongning tablet placebo,3tablets,bid,treat 12 weeks
Trial: NCT01445587
Drug: Part 2; Stage 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the completion of PK sampling and the determination of a Recommended Phase 2 Dose (RP2D) of GSK2110183 in Cohorts 1 and 2, subjects will be enrolled into Part 2, Stage 1 of the study. Twenty subjects will be enrolled in Stage 1. If no subject responds, the study will be stopped; otherwise, the study will continue enrollment of Stage 2.
Trial: NCT03962634
Drug: Kovanaze Nasal Spray
RxNorm normalized name: Kovanaze Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-nasal local anesthetic
Trial: NCT04074265
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection containing normal saline will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
Trial: NCT02425306
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide, systemic adjuvant
Trial: NCT01445587
Drug: Part 2, Stage 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty subjects will be enrolled in Part 2, Stage 2. If 4 or fewer of the 40 subjects (Stages 1 and 2) respond, the study will not be deemed as a success for GSK2110183 monotherapy. However, those subjects meeting the criteria for progression (as defined by IMWC Panel 1) who also meet the additional eligibility criteria for salvage therapy may proceed to GSK2110183 + bortezomib salvage therapy. GSK2110183 + bortezomib salvage therapy will be continued until one of the Treatment Discontinuation Criteria is met
Trial: NCT00018278
Drug: Nicoderm Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04355247
Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension
RxNorm normalized name: methylPREDNISolone 80 mg/mL injectable suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Patients will be admitted to a regular room in the hospital (not ICU)~* They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.~* Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital.
Trial: NCT01255163
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SC twice daily
Trial: NCT03460041
Drug: Dexmetedomedine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal dexmetedomedine added to bupivacaine for pain management
Trial: NCT01261637
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20ml saline
Trial: NCT03716115
Drug: N-Acetyl Glucosamine (GInNAC)
RxNorm normalized name: N-acetyl-glucosamine thiazoline
DrugBank: N-Acetyl-glucosamine thiazoline (DB03747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-Acetyl glucosamine provided as powder will be reconstituted and administered orally or via NG tube.
Trial: NCT02807103
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.
Trial: NCT02807103
Drug: Placebo-cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.
Trial: NCT01028027
Drug: Loteprednol and tobramycin
RxNorm normalized name: Loteprednol and tobramycin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
Trial: NCT04204603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT03758924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral solution